中药提取物调控铁死亡改善阿尔茨海默病的研究新进展

doi:10.12114/j.issn.1007-9572.2024.0295

中国全科医学 ›› 2025, Vol. 28 ›› Issue (05): 639-648.DOI: 10.12114/j.issn.1007-9572.2024.0295

• 综述与专论 • 上一篇

中药提取物调控铁死亡改善阿尔茨海默病的研究新进展

裴金英¹, 宋金洲¹, 马到丰¹, 罗孝廷¹, 刘斌¹^,^*(), 董晓红¹, 丛树园²

1．150040　黑龙江省哈尔滨市，黑龙江中医药大学
2．650500　云南省昆明市，云南中医药大学

收稿日期:2024-07-10 修回日期:2024-08-25 出版日期:2025-02-15 发布日期:2024-11-25
通讯作者: 刘斌
作者贡献：
裴金英提出研究命题，进行文章的构思与撰写；宋金洲、马到丰进行文献的检索与收集；罗孝廷、董晓红、丛树园进行论文修订；刘斌负责文章的质量控制及审校，并对文章整体负责。
基金资助:
黑龙江省自然科学基金项目(LH2023H073)

Research Progress in the Study of Traditional Chinese Herbal Medicine Extracts Regulating Ferroptosis thus Improving the Symptom of Alzheimer's Disease

PEI Jinying¹, SONG Jinzhou¹, MA Daofeng¹, LUO Xiaoting¹, LIU Bin¹^,^*(), DONG Xiaohong¹, CONG Shuyuan²

1. Heilongjiang University of Chinese Medicine, Harbin 150040, China
2. Yunnan University of Chinese Medicine, Kunming 650500, China

Received:2024-07-10 Revised:2024-08-25 Published:2025-02-15 Online:2024-11-25
Contact: LIU Bin

摘要/Abstract

摘要： 阿尔茨海默病（AD）是一种老年人群中常见的神经退行性疾病，其典型临床表现是进行性记忆障碍。铁死亡是近些年新兴起的潜在的生物学机制研究方向，是一种铁依赖性程序性细胞死亡方式，大量证据表明AD与大脑中的铁死亡密切相关，然而其参与AD的确切机制尚不清楚，其可能由铁代谢紊乱、脂质过氧化和氨基酸代谢诱导，从而影响大脑中铁离子的沉积。迄今为止，部分中药有效化学成分已被深入研究，例如红景天、远志、银杏、茯苓等，这些中药在靶向铁死亡治疗AD的过程中展现出了显著的效果。在此背景下，本综述系统阐述了大脑中铁的代谢、铁死亡的特点，并重点关注铁死亡代谢调控机制。同时，本文还讨论了铁死亡和AD的联系，并同时列举了中药的有效成分通过抑制铁死亡改善AD的药物，以期为今后铁死亡抑制剂的开发研究提供参考信息。

关键词: 阿尔茨海默病, 中药, 铁死亡, 作用机制, 综述

Abstract:

Alzheimer's disease (AD) is a common neurodegenerative disease in the elderly population. It's typical clinical manifestation is progressive memory impairment. Ferroptosis, rising as a new research direction on AD biological mechanism in recent years, mainly studies on iron-dependent programmed cell death. A large amount of evidence has shown that AD is closely related to ferroptosis in the brain. However, the exact mechanism of the role ferroptosis has played in AD is still unclear. One of the most popular research results indicates that AD might be induced by iron metabolism disorders, lipid peroxidation, and amino acid metabolism, thereby affecting the deposition of iron ions in the brain. So far, some effective chemical components of traditional Chinese herbs as cures of AD have been studied in depth, such as rhodiola rosea, polygala root, ginkgo biloba, poria cocos, etc. These traditional Chinese herbs have shown remarkable effects in the treatment of AD by means of targeting ferroptosis. In this context, this review systematically elaborates on the metabolism of iron in the brain, the characteristics of ferroptosis, and focuses on the metabolic regulation mechanism of ferroptosis. Meanwhile, this review also discusses the connection between ferroptosis and AD. Furthermore, it lists the effective compositions in traditional Chinese herbs that can improve AD by inhibiting ferroptosis, so as to provide reference information for the development and research of ferroptosis inhibitors in the future.

Key words: Alzheimer's disease, Traditional Chinese drugs, Ferroptosis, Mechanism of action, Review

中图分类号:

R 745.7

裴金英,宋金洲,马到丰,等. 中药提取物调控铁死亡改善阿尔茨海默病的研究新进展[J]. 中国全科医学, 2025, 28(05): 639-648. DOI: 10.12114/j.issn.1007-9572.2024.0295.
PEI Jinying,SONG Jinzhou,MA Daofeng, et al. Research Progress in the Study of Traditional Chinese Herbal Medicine Extracts Regulating Ferroptosis thus Improving the Symptom of Alzheimer's Disease[J]. Chinese General Practice, 2025, 28(05): 639-648. DOI: 10.12114/j.issn.1007-9572.2024.0295.

图/表 1

参考文献 81

[1]	ALZHEIMER A, STELZMANN R A, SCHNITZLEIN H N, et al. An English translation of Alzheimer's 1907 paper，"Uber eine eigenartige Erkankung der Hirnrinde" [J]. Clin Anat，1995，8(6):429-431. DOI：10.1002/ca.980080612.
[2]	JIA L F, DU Y F, CHU L, et al. Prevalence，risk factors，and management of dementia and mild cognitive impairment in adults aged 60 years or older in China：a cross-sectional study[J]. Lancet Public Health，2020，5(12):e661-671. DOI：10.1016/S2468-2667(20)30185-7.
[3]	SCHELTENS P, DE STROOPER B, KIVIPELTO M, et al. Alzheimer's disease[J]. Lancet，2021，397(10284):1577-1590. DOI：10.1016/S0140-6736(20)32205-4.
[4]	DIXON S J, LEMBERG K M, LAMPRECHT M R, et al. Ferroptosis：an iron-dependent form of nonapoptotic cell death[J]. Cell，2012，149(5):1060-1072. DOI：10.1016/j.cell.2012.03.042.
[5]	LI L B, CHAI R, ZHANG S, et al. Iron exposure and the cellular mechanisms linked to neuron degeneration in adult mice[J]. Cells，2019，8(2):198. DOI：10.3390/cells8020198.
[6]	李燕新，吕占云，李维，等. 铁死亡相关蛋白在AD小鼠海马中的表达[J]. 中国神经精神疾病杂志，2018，44(12):727-731. DOI：10.3969/j.issn.1002-0152.2018.12.008.
[7]	LEI P, AYTON S, BUSH A I. The essential elements of Alzheimer's disease[J]. J Biol Chem，2021，296:100105. DOI：10.1074/jbc.REV120.008207.
[8]	XIONG H, TUO Q Z, GUO Y J, et al. Diagnostics and treatments of iron-related CNS diseases[J]. Adv Exp Med Biol，2019，1173:179-194. DOI：10.1007/978-981-13-9589-5_10.
[9]	DUCK K A, SIMPSON I A, CONNOR J R. Regulatory mechanisms for iron transport across the blood-brain barrier[J]. Biochem Biophys Res Commun，2017，494(1/2):70-75. DOI：10.1016/j.bbrc.2017.10.083.
[10]	QIAN Z M, KE Y. Brain iron transport[J]. Biol Rev Camb Philos Soc，2019，94(5):1672-1684. DOI：10.1111/brv.12521.
[11]	MURRAY-KOLB L E. Iron and brain functions[J]. Curr Opin Clin Nutr Metab Care，2013，16(6):703-707. DOI：10.1097/MCO.0b013e3283653ef8.
[12]	ASHRAF A, JEANDRIENS J, PARKES H G, et al. Iron dyshomeostasis，lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer's disease：evidence of ferroptosis[J]. Redox Biol，2020，32:101494. DOI：10.1016/j.redox.2020.101494.
[13]	AYTON S, WANG Y M, DIOUF I, et al. Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology[J]. Mol Psychiatry，2020，25(11):2932-2941. DOI：10.1038/s41380-019-0375-7.
[14]	CHU J, LI J W, SUN L, et al. The role of cellular defense systems of ferroptosis in Parkinson's disease and Alzheimer's disease[J]. Int J Mol Sci，2023，24(18):14108. DOI：10.3390/ijms241814108.
[15]	WANG H, AN P, XIE E J, et al. Characterization of ferroptosis in murine models of hemochromatosis[J]. Hepatology，2017，66(2):449-465. DOI：10.1002/hep.29117.
[16]	RAHA A A, VAISHNAV R A, FRIEDLAND R P, et al. The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease[J]. Acta Neuropathol Commun，2013，1:55. DOI：10.1186/2051-5960-1-55.
[17]	COSTA I, BARBOSA D J, BENFEITO S, et al. Molecular mechanisms of ferroptosis and their involvement in brain diseases[J]. Pharmacol Ther，2023，244:108373. DOI：10.1016/j.pharmthera.2023.108373.
[18]	SUN X F, OU Z H, CHEN R C, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells[J]. Hepatology，2016，63(1):173-184. DOI：10.1002/hep.28251.
[19]	KENKHUIS B, BUSH A I, AYTON S. How iron can drive neurodegeneration[J]. Trends Neurosci，2023，46(5):333-335. DOI：10.1016/j.tins.2023.02.003.
[20]	YAMAMOTO A, SHIN R W, HASEGAWA K, et al. Iron（Ⅲ）induces aggregation of hyperphosphorylated tau and its reduction to iron（Ⅱ）reverses the aggregation：implications in the formation of neurofibrillary tangles of Alzheimer's disease[J]. J Neurochem，2002，82(5):1137-1147. DOI：10.1046/j.1471-4159.2002.t01-1-01061.x.
[21]	WU J, YANG J J, CAO Y, et al. Iron overload contributes to general anaesthesia-induced neurotoxicity and cognitive deficits[J]. J Neuroinflammation，2020，17(1):110. DOI：10.1186/s12974-020-01777-6.
[22]	BENSENY-CASES N, KLEMENTIEVA O, COTTE M, et al. Microspectroscopy（μFTIR）reveals co-localization of lipid oxidation and amyloid plaques in human Alzheimer disease brains[J]. Anal Chem，2014，86(24):12047-12054. DOI：10.1021/ac502667b.
[23]	LANE D J R, METSELAAR B, GREENOUGH M, et al. Ferroptosis and NRF2：an emerging battlefield in the neurodegeneration of Alzheimer's disease[J]. Essays Biochem，2021，65(7):925-940. DOI：10.1042/EBC20210017.
[24]	DOLL S, PRONETH B, TYURINA Y Y, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition[J]. Nat Chem Biol，2017，13(1):91-98. DOI：10.1038/nchembio.2239.
[25]	DIXON S J, WINTER G E, MUSAVI L S, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death[J]. ACS Chem Biol，2015，10(7):1604-1609. DOI：10.1021/acschembio.5b00245.
[26]	SHINTOKU R, TAKIGAWA Y, YAMADA K, et al. Lipoxygenase-mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3[J]. Cancer Sci，2017，108(11):2187-2194. DOI：10.1111/cas.13380.
[27]	ANGELI J P F, SHAH R, PRATT D A, et al. Ferroptosis inhibition：mechanisms and opportunities[J]. Trends Pharmacol Sci，2017，38(5):489-498. DOI：10.1016/j.tips.2017.02.005.
[28]	INGOLD I, BERNDT C, SCHMITT S, et al. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis[J]. Cell，2018，172(3):409-422.e21. DOI：10.1016/j.cell.2017.11.048.
[29]	NADERI S, KHODAGHOLI F, POURBADIE H G, et al. Role of amyloid beta（25-35）neurotoxicity in the ferroptosis and necroptosis as modalities of regulated cell death in Alzheimer's disease[J]. Neurotoxicology，2023，94:71-86. DOI：10.1016/j.neuro.2022.11.003.
[30]	FARESJÖ R, SEHLIN D, SYVÄNEN S. Age，dose，and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody[J]. Fluids Barriers CNS，2023，20(1):34. DOI：10.1186/s12987-023-00435-2.
[31]	BRANDSMA M E, JEVNIKAR A M, MA S W. Recombinant human transferrin：beyond iron binding and transport[J]. Biotechnol Adv，2011，29(2):230-238. DOI：10.1016/j.biotechadv.2010.11.007.
[32]	ZHANG N, YU X Q, XIE J X, et al. New insights into the role of ferritin in iron homeostasis and neurodegenerative diseases[J]. Mol Neurobiol，2021，58(6):2812-2823. DOI：10.1007/s12035-020-02277-7.
[33]	ANDERSON G J, FRAZER D M. Current understanding of iron homeostasis[J]. Am J Clin Nutr，2017，106(Suppl 6):1559S-1566S. DOI：10.3945/ajcn.117.155804.
[34]	CHEN K, JIANG X B, WU M X, et al. Ferroptosis，a potential therapeutic target in Alzheimer's disease[J]. Front Cell Dev Biol，2021，9:704298. DOI：10.3389/fcell.2021.704298.
[35]	RAVEN E P, LU P H, TISHLER T A, et al. Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging[J]. J Alzheimers Dis，2013，37(1):127-136. DOI：10.3233/JAD-130209.
[36]	LI J, CAO F, YIN H L, et al. Ferroptosis：past，present and future[J]. Cell Death Dis，2020，11(2):88. DOI：10.1038/s41419-020-2298-2.
[37]	AYTON S, FAZLOLLAHI A, BOURGEAT P, et al. Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline[J]. Brain，2017，140(8):2112-2119. DOI：10.1093/brain/awx137.
[38]	HAMBRIGHT W S, FONSECA R S, CHEN L J, et al. Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration[J]. Redox Biol，2017，12:8-17. DOI：10.1016/j.redox.2017.01.021.
[39]	PARK M W, CHA H W, KIM J, et al. NOX4 promotes ferroptosis of astrocytes by oxidative stress-induced lipid peroxidation via the impairment of mitochondrial metabolism in Alzheimer's diseases[J]. Redox Biol，2021，41:101947. DOI：10.1016/j.redox.2021.101947.
[40]	DANG Y N, HE Q, YANG S Y, et al. FTH1- and SAT1-induced astrocytic ferroptosis is involved in Alzheimer's disease：evidence from single-cell transcriptomic analysis[J]. Pharmaceuticals，2022，15(10):1177. DOI：10.3390/ph15101177.
[41]	BAO W D, PANG P, ZHOU X T, et al. Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer's disease[J]. Cell Death Differ，2021，28(5):1548-1562. DOI：10.1038/s41418-020-00685-9.
[42]	ZHENG J B, ZHANG J Z, HAN J, et al. The effect of salidroside in promoting endogenous neural regeneration after cerebral ischemia/reperfusion involves notch signaling pathway and neurotrophic factors[J]. BMC Complementary Medicine and Therapies，2024，24(1):293. DOI10.1186/s12906-024-04597-w.
[43]	YANG S X, WANG L S, ZENG Y, et al. Salidroside alleviates cognitive impairment by inhibiting ferroptosis via activation of the Nrf2/GPX4 axis in SAMP8 mice[J]. Phytomedicine，2023，114:154762. DOI：10.1016/j.phymed.2023.154762.
[44]	YANG S X, XIE Z P, PEI T T, et al. Salidroside attenuates neuronal ferroptosis by activating the Nrf2/HO1 signaling pathway in Aβ1-42-induced Alzheimer's disease mice and glutamate-injured HT22 cells[J]. Chin Med，2022，17(1):82. DOI：10.1186/s13020-022-00634-3.
[45]	ZHANG L Y, LANG F L, FENG J, et al. Review of the therapeutic potential of Forsythiae Fructus on the central nervous system：active ingredients and mechanisms of action[J]. J Ethnopharmacol，2024，319(Pt 2):117275. DOI：10.1016/j.jep.2023.117275.
[46]	WANG C Y, CHEN S S, GUO H Y, et al. Forsythoside A mitigates alzheimer's-like pathology by inhibiting ferroptosis-mediated neuroinflammation via Nrf2/GPX4 axis activation[J]. Int J Biol Sci，2022，18(5):2075-2090. DOI：10.7150/ijbs.69714.
[47]	WANG Y S, SHEN C Y, JIANG J G. Antidepressant active ingredients from herbs and nutraceuticals used in TCM：pharmacological mechanisms and prospects for drug discovery[J]. Pharmacol Res，2019，150:104520. DOI：10.1016/j.phrs.2019.104520.
[48]	ZHAI L P, PEI H Y, SHEN H P, et al. Paeoniflorin suppresses neuronal ferroptosis to improve the cognitive behaviors in Alzheimer's disease mice[J]. Phytother Res，2023，37(10):4791-4800. DOI：10.1002/ptr.7946.
[49]	JIN J, WANG H, HUA X Y, et al. An outline for the pharmacological effect of icariin in the nervous system[J]. Eur J Pharmacol，2019，842:20-32. DOI：10.1016/j.ejphar.2018.10.006.
[50]	YANG Y, FU Y M, QIN Z P, et al. Icariin improves cognitive impairment by inhibiting ferroptosis of nerve cells[J]. Aging，2023，15(20):11546-11553. DOI：10.18632/aging.205144.
[51]	LI M H, LU W, MENG Y Y, et al. Tetrahydroxy stilbene glucoside alleviates ischemic stroke by regulating conformation-dependent intracellular distribution of PKM2 for M2 macrophage polarization[J]. J Agric Food Chem，2022，70(49):15449-15463. DOI：10.1021/acs.jafc.2c03923.
[52]	GAO Y, LI J T, WU Q L, et al. Tetrahydroxy stilbene glycoside ameliorates Alzheimer's disease in APP/PS1 mice via glutathione peroxidase related ferroptosis[J]. Int Immunopharmacol，2021，99:108002. DOI：10.1016/j.intimp.2021.108002.
[53]	CHEN Z, YANG Y, HAN Y, et al. Neuroprotective effects and mechanisms of senegenin，an effective compound originated from the roots of Polygala tenuifolia[J]. Front Pharmacol，2022，13:937333. DOI：10.3389/fphar.2022.937333.
[54]	ZHANG H P, ZHOU W, LI J L, et al. Senegenin rescues PC12 cells with oxidative damage through inhibition of ferroptosis[J]. Mol Neurobiol，2022，59(11):6983-6992. DOI：10.1007/s12035-022-03014-y.
[55]	LI C T, GAO F, QU Y, et al. Tenuifolin in the prevention of Alzheimer's disease-like phenotypes：investigation of the mechanisms from the perspectives of calpain system，ferroptosis，and apoptosis[J]. Phytother Res，2023:4621-4638. DOI：10.1002/ptr.7930.
[56]	SHAO L, DONG C, GENG D Q, et al. Ginkgolide B protects against cognitive impairment in senescence-accelerated P8 mice by mitigating oxidative stress，inflammation and ferroptosis[J]. Biochem Biophys Res Commun，2021，572:7-14. DOI：10.1016/j.bbrc.2021.07.081.
[57]	ZHANG Y D, ZHAO Y, ZHANG J, et al. Quantitative proteomics reveals neuroprotective mechanism of ginkgolide B in Aβ1-42-induced N2a neuroblastoma cells[J]. J Integr Neurosci，2023，22(2):33. DOI：10.31083/j.jin2202033.
[58]	SHOU J W, SHAW P C. Therapeutic efficacies of berberine against neurological disorders：an update of pharmacological effects and mechanisms[J]. Cells，2022，11(5):796. DOI：10.3390/cells11050796.
[59]	LI X, CHEN J, FENG W, et al. Berberine ameliorates iron levels and ferroptosis in the brain of 3×Tg-AD mice[J]. Phytomedicine，2023，118:154962. DOI：10.1016/j.phymed.2023.154962.
[60]	LE J M, JI H L, ZHOU X X, et al. Pharmacology，toxicology，and metabolism of sennoside A，a medicinal plant-derived natural compound[J]. Front Pharmacol，2021，12:714586. DOI：10.3389/fphar.2021.714586.
[61]	LI X J, WANG X P, HUANG B, et al. Sennoside A restrains TRAF6 level to modulate ferroptosis，inflammation and cognitive impairment in aging mice with Alzheimer's Disease[J]. Int Immunopharmacol，2023，120:110290. DOI：10.1016/j.intimp.2023.110290.
[62]	TANG J J, WANG M R, DONG S, et al. 1，10-Seco-Eudesmane sesquiterpenoids as a new type of anti-neuroinflammatory agents by suppressing TLR4/NF-κB/MAPK pathways[J]. Eur J Med Chem，2021，224:113713. DOI：10.1016/j.ejmech.2021.113713.
[63]	TANG J J, HUANG L F, DENG J L, et al. Cognitive enhancement and neuroprotective effects of OABL，a sesquiterpene lactone in 5xFAD Alzheimer's disease mice model[J]. Redox Biol，2022，50:102229. DOI：10.1016/j.redox.2022.102229.
[64]	LEE E, JEONG K W, SHIN A, et al. Binding model for eriodictyol to Jun-N terminal kinase and its anti-inflammatory signaling pathway[J]. BMB Rep，2013，46(12):594-599. DOI：10.5483/bmbrep.2013.46.12.092.
[65]	WANG X, DENG R, DONG J Y, et al. Eriodictyol ameliorates lipopolysaccharide-induced acute lung injury by suppressing the inflammatory COX-2/NLRP3/NF-κB pathway in mice[J]. J Biochem Mol Toxicol，2020，34(3):e22434. DOI：10.1002/jbt.22434.
[66]	LI L, LI W J, ZHENG X R, et al. Eriodictyol ameliorates cognitive dysfunction in APP/PS1 mice by inhibiting ferroptosis via vitamin D receptor-mediated Nrf2 activation[J]. Mol Med，2022，28(1):11. DOI：10.1186/s10020-022-00442-3.
[67]	PAYNE A, NAHASHON S, TAKA E, et al. Epigallocatechin-3-gallate（EGCG）：new therapeutic perspectives for neuroprotection，aging，and neuroinflammation for the modern age[J]. Biomolecules，2022，12(3):371. DOI：10.3390/biom12030371.
[68]	REZNICHENKO L, AMIT T, ZHENG H, et al. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by（-）-epigallocatechin-3-gallate in cell cultures：implications for iron chelation in Alzheimer's disease[J]. J Neurochem，2006，97(2):527-536. DOI：10.1111/j.1471-4159.2006.03770.x.
[69]	VALVERDE-SALAZAR V, RUIZ-GABARRE D, GARCÍA-ESCUDERO V. Alzheimer's disease and green tea：epigallocatechin-3-gallate as a modulator of inflammation and oxidative stress[J]. Antioxidants，2023，12(7):1460. DOI：10.3390/antiox12071460.
[70]	YANG S J, SONG Z J, WANG X C, et al. Curculigoside facilitates fear extinction and prevents depression-like behaviors in a mouse learned helplessness model through increasing hippocampal BDNF[J]. Acta Pharmacol Sin，2019，40(10):1269-1278. DOI：10.1038/s41401-019-0238-4.
[71]	GONG Y H, WANG Y N, LI Y F, et al. Curculigoside，a traditional Chinese medicine monomer，ameliorates oxidative stress in Alzheimer's disease mouse model via suppressing ferroptosis[J]. Phytother Res，2024，38(5):2462-2481. DOI：10.1002/ptr.8152.
[72]	MORALES I, CERDA-TRONCOSO C, ANDRADE V, et al. The natural product curcumin as a potential coadjuvant in Alzheimer's treatment[J]. J Alzheimers Dis，2017，60(2):451-460. DOI：10.3233/JAD-170354.
[73]	SU S Y, WU J S, GAO Y, et al. The pharmacological properties of chrysophanol，the recent advances[J]. Biomed Pharmacother，2020，125:110002. DOI：10.1016/j.biopha.2020.110002.
[74]	LUO J, LU Q Y, SUN B, et al. Chrysophanol improves memory impairment and cell injury by reducing the level of ferroptosis in A β25-35 treated rat and PC12 cells[J]. 3 Biotech，2023，13(11):348. DOI：10.1007/s13205-023-03769-8.
[75]	XIE D N, DENG T, ZHAI Z W, et al. Moschus exerted protective activity against H₂O₂-induced cell injury in PC12 cells through regulating Nrf-2/ARE signaling pathways[J]. Biomed Pharmacother，2023，159:114290. DOI：10.1016/j.biopha.2023.114290.
[76]	SONG C Y, CHU Z L, DAI J Y, et al. Water extract of moschus alleviates erastin-induced ferroptosis by regulating the Keap1/Nrf2 pathway in HT22 cells[J]. J Ethnopharmacol，2024，326:117937. DOI：10.1016/j.jep.2024.117937.
[77]	HU S Y, YANG B L, LI B B, et al. RNA-seq analysis reveals potential neuroprotective mechanisms of pachymic acid toward iron-induced oxidative stress and cell death[J]. Cell Transplant，2024，33:9636897231218382. DOI：10.1177/09636897231218382.
[78]	樊赟，窦润鹏，胡久略，等. 茯苓酸通过Nrf2/SLC7A11/GPX4信号通路调控铁死亡改善阿尔茨海默病大鼠认知障碍的研究[J]. 中国全科医学，2024，27(2):177-183. DOI：10.12114/j.issn.1007-9572.2023.0326.
[79]	FINE J M, KOSYAKOVSKY J, BAILLARGEON A M, et al. Intranasal deferoxamine can improve memory in healthy C57 mice，suggesting a partially non-disease-specific pathway of functional neurologic improvement[J]. Brain Behav，2020，10(3):e01536. DOI：10.1002/brb3.1536.
[80]	刘珊，贺小平，赵炎，等. 淫黄葛合剂对APP/PS1 HAMP-/-小鼠认知功能和铁死亡氨基酸代谢通路的影响[J]. 中国病理生理杂志，2024，40(3):502-510. DOI：10.3969/j.issn.1000-4718.2024.03.014.
[81]	LONG Q H, LI T, ZHU Q H, et al. SuanZaoRen decoction alleviates neuronal loss，synaptic damage and ferroptosis of AD via activating DJ-1/Nrf2 signaling pathway[J]. J Ethnopharmacol，2024，323:117679. DOI：10.1016/j.jep.2023.117679.

有效成分	模型	剂量	靶点
红景天苷	SAMP8小鼠	30 mg/kg	Aβ1-42、铁沉积、MDA、IL-1β、IFN-γ、TNF-α、ACSL4、TFR1↓、GSH、SOD、IL-10、GPX4、SLC7A11、SLC3A2、FTH1、Fpn1、Nrf2、HO-1↑
红景天苷	Nrf2基因敲除小鼠、C57BL/6小鼠	50 mg/kg	MDA↓、SOD↑、GSH/GSSG↑、GPX4↑、SLC7A11↑、HO-1↑、ROS↓、Nrf2↑、Fe²⁺↓、PTGS2↓
连翘酯苷A	APP/PS1小鼠	30 mg/kg	MDA↓、MMP，Aβ1-42、p-tau、NO↓、IL-4↑、IL-10↑、IL-1β↓、IL-6↓、Fe、GPX4↑、xCT↑、FTL↑、Fpn↑、DRD1↑、CREB↑、BDNF↑、TrkB↑、PI3K、p-AKT、GNAL↑、Adcy5↑、cAMP↑、p-Fyn↓、p-GSK-3β↑、Nrf2↑、TFRC↓、DMT1↓、FTH↑、Iba1↓、GFAP↓、TGF-β↑、MCP-1↓、ALOX5↓、CD33↓、iNOS↓、TNF-α↓、IKK↓
芍药苷	C57BL/6小鼠、APP/PS1小鼠	10 mg/kg	Fe³⁺↓、SOD↑、MDA↓、JC-1↑、P53↓、STAT3、GPX4↑、GAPDH、ΔΨm
淫羊藿苷	APP/PS1小鼠、C57BL/6小鼠	5、10 mg/kg	MDA↓、SOD↑、MDM2、GSH-Px↑、LDH↓、GSH↑、caspase-3↓、Fe↓、p53↓、Aβ25-35↓、p-Tau
何首乌苷	APP/PS1小鼠、C57BL/6小鼠	60、120、180 mg/kg	Aβ↓、GSS、SOD1、SOD2、Prdx1、8-OHdG↓、Nrf2↑、Keap1↑、HO-1↑、NQO1↑、GCLC↑、GCLM↑、NLRP3↓、TXNIP↓、TXNRD1↓、iNOS↓、GPX4↑、xCT、GPX4↑、GPX1↑、FTH1↑、xCT↑、CD98↑、DMT1↓、ACSL4↓、NCOA4↓、FTH↓、FTL↓
远志皂苷元	Aβ25-35诱导的PC12细胞	15、30、60、120、240 μmol/L	ACSL4↓、PEBP1↓、GPX4↑、ROS↓、MDA、GAPDH
细叶远志皂苷	C57BL/6小鼠	10 mg/kg	AKT、STAT3、CASP3、BDNF↑、PSD95↑、p-TrkB↑、Actin、p-Akt↑、mRNA↑、Ca²⁺↓、m-calpain↓、calpastatin↑、MDA↓、GSH↑、SOD↑、CAT↑、ROS↓、MFI↓、ACSL4↓、GPX4↑、SLC7A11↑、SYN
银杏内酯B	SAMR1小鼠、SAMP8小鼠	20、30、40 mg/kg	GFAP、Iba-1、TNF-a、IL-1b、IL-6、SOD↑、GSH↑、MDA↓、NO↓、ROS↓、GPX4↑、Fe²⁺↓、TFR1、NCOA4、FTH1↑、Nrf2↑、RSL3、GAPDH、Lamin B1、DAPI
	Aβ1-42诱导的N2a细胞	100 μmol/L	FTH1↑、SPP1↓、ROS↓、SOD↑、MDA↓、SLC7A11↓、Psen2、Fn1↑、Ftl1↑、Syn1↓、Apom↓
小檗碱	3×Tg-AD小鼠、WT小鼠	50 mg/kg	APP↓、Bace1↓、Aβ1-42↓、ADAM10↑、P-tau↓、Fe³⁺、Fe²⁺、FTH1、TFR、GSH↑、MDA↓、GPX4↑、SLC7A11↑、ACSL4↓、Nrf2、Keap1、4HNE↓、Fpn1、
番泻苷A	C57BL/6小鼠、APP/PS1小鼠	7.5、15、30 mg/kg	caspase-3↓、PARP-1↓、GSH↑、MDA↓、ROS、IL-1β↓、IL-6↓、TNF-α↓、TRAF6↓、p-P65↓
旋覆花内酯	5xFAD小鼠、C57BL6小鼠	20 mg/kg	TNF-α↓、PGE2↓、IL-10↑、Arg-1↑、iNOS↓、COX-2↓、GPx4、GSH↑、MDA↓、T-SOD↓、BACE1↓、Aβ↓、p-Tau↓、GFAP↓、Iba-1↓
圣草酚	APP/PS1小鼠	50 mg/kg	Aβ↓、p-Tau↓、TfRC↓、FTH↓、Fpn↑、MDA↓、GPX4↑、ROS、mRNA↑、p-Nrf2↑、VDR、HO-1↑
表没食子儿茶素没食子酸酯	DNL细胞、CHO细胞	1~10 μmol/L	TfR↑、β-actin、Aβ↓、holo-APP↓、IRPs、APP、sAPPα↑、mRNA
仙茅苷	ICR小鼠	50、100 mg/kg	GPX4↑、SLC7A11↓、MDA↓、Fe↓、GSH↑、GSH/GSSG↑、GAPDH、GCLM↑、GCLC↑、ROS↓、LIP、Aβ1-42↓、ACSL4↓、p-BECN1↑、p-Tau↓、FPN↑、STEAP3、DMT1
大黄酚	SD大鼠（D-半乳糖造模）	0.036 mg/mL	GPx↑、GSH↑、GPX4↑、ROS↓、GAPDH、Aβ
麝香水提物	HT22细胞	330 μg/mL、60 μg/mL	MDA↓、GSH↑、ROS↓、GPX4↑、SLC7A11↑、TFRC↓、Fpn1↑、FTH1↑、Fe²⁺、Nrf2、Keap1↓、HO-1、FTH1
茯苓酸	SD大鼠（Aβ25-35诱导）	50 mg/kg	Nrf2、SLC7A11、GPX4↑、GSH↑、MDA↓、Fe²⁺↓

有效成分	模型	剂量	靶点
红景天苷	SAMP8小鼠	30 mg/kg	Aβ1-42、铁沉积、MDA、IL-1β、IFN-γ、TNF-α、ACSL4、TFR1↓、GSH、SOD、IL-10、GPX4、SLC7A11、SLC3A2、FTH1、Fpn1、Nrf2、HO-1↑
红景天苷	Nrf2基因敲除小鼠、C57BL/6小鼠	50 mg/kg	MDA↓、SOD↑、GSH/GSSG↑、GPX4↑、SLC7A11↑、HO-1↑、ROS↓、Nrf2↑、Fe²⁺↓、PTGS2↓
连翘酯苷A	APP/PS1小鼠	30 mg/kg	MDA↓、MMP，Aβ1-42、p-tau、NO↓、IL-4↑、IL-10↑、IL-1β↓、IL-6↓、Fe、GPX4↑、xCT↑、FTL↑、Fpn↑、DRD1↑、CREB↑、BDNF↑、TrkB↑、PI3K、p-AKT、GNAL↑、Adcy5↑、cAMP↑、p-Fyn↓、p-GSK-3β↑、Nrf2↑、TFRC↓、DMT1↓、FTH↑、Iba1↓、GFAP↓、TGF-β↑、MCP-1↓、ALOX5↓、CD33↓、iNOS↓、TNF-α↓、IKK↓
芍药苷	C57BL/6小鼠、APP/PS1小鼠	10 mg/kg	Fe³⁺↓、SOD↑、MDA↓、JC-1↑、P53↓、STAT3、GPX4↑、GAPDH、ΔΨm
淫羊藿苷	APP/PS1小鼠、C57BL/6小鼠	5、10 mg/kg	MDA↓、SOD↑、MDM2、GSH-Px↑、LDH↓、GSH↑、caspase-3↓、Fe↓、p53↓、Aβ25-35↓、p-Tau
何首乌苷	APP/PS1小鼠、C57BL/6小鼠	60、120、180 mg/kg	Aβ↓、GSS、SOD1、SOD2、Prdx1、8-OHdG↓、Nrf2↑、Keap1↑、HO-1↑、NQO1↑、GCLC↑、GCLM↑、NLRP3↓、TXNIP↓、TXNRD1↓、iNOS↓、GPX4↑、xCT、GPX4↑、GPX1↑、FTH1↑、xCT↑、CD98↑、DMT1↓、ACSL4↓、NCOA4↓、FTH↓、FTL↓
远志皂苷元	Aβ25-35诱导的PC12细胞	15、30、60、120、240 μmol/L	ACSL4↓、PEBP1↓、GPX4↑、ROS↓、MDA、GAPDH
细叶远志皂苷	C57BL/6小鼠	10 mg/kg	AKT、STAT3、CASP3、BDNF↑、PSD95↑、p-TrkB↑、Actin、p-Akt↑、mRNA↑、Ca²⁺↓、m-calpain↓、calpastatin↑、MDA↓、GSH↑、SOD↑、CAT↑、ROS↓、MFI↓、ACSL4↓、GPX4↑、SLC7A11↑、SYN
银杏内酯B	SAMR1小鼠、SAMP8小鼠	20、30、40 mg/kg	GFAP、Iba-1、TNF-a、IL-1b、IL-6、SOD↑、GSH↑、MDA↓、NO↓、ROS↓、GPX4↑、Fe²⁺↓、TFR1、NCOA4、FTH1↑、Nrf2↑、RSL3、GAPDH、Lamin B1、DAPI
	Aβ1-42诱导的N2a细胞	100 μmol/L	FTH1↑、SPP1↓、ROS↓、SOD↑、MDA↓、SLC7A11↓、Psen2、Fn1↑、Ftl1↑、Syn1↓、Apom↓
小檗碱	3×Tg-AD小鼠、WT小鼠	50 mg/kg	APP↓、Bace1↓、Aβ1-42↓、ADAM10↑、P-tau↓、Fe³⁺、Fe²⁺、FTH1、TFR、GSH↑、MDA↓、GPX4↑、SLC7A11↑、ACSL4↓、Nrf2、Keap1、4HNE↓、Fpn1、
番泻苷A	C57BL/6小鼠、APP/PS1小鼠	7.5、15、30 mg/kg	caspase-3↓、PARP-1↓、GSH↑、MDA↓、ROS、IL-1β↓、IL-6↓、TNF-α↓、TRAF6↓、p-P65↓
旋覆花内酯	5xFAD小鼠、C57BL6小鼠	20 mg/kg	TNF-α↓、PGE2↓、IL-10↑、Arg-1↑、iNOS↓、COX-2↓、GPx4、GSH↑、MDA↓、T-SOD↓、BACE1↓、Aβ↓、p-Tau↓、GFAP↓、Iba-1↓
圣草酚	APP/PS1小鼠	50 mg/kg	Aβ↓、p-Tau↓、TfRC↓、FTH↓、Fpn↑、MDA↓、GPX4↑、ROS、mRNA↑、p-Nrf2↑、VDR、HO-1↑
表没食子儿茶素没食子酸酯	DNL细胞、CHO细胞	1~10 μmol/L	TfR↑、β-actin、Aβ↓、holo-APP↓、IRPs、APP、sAPPα↑、mRNA
仙茅苷	ICR小鼠	50、100 mg/kg	GPX4↑、SLC7A11↓、MDA↓、Fe↓、GSH↑、GSH/GSSG↑、GAPDH、GCLM↑、GCLC↑、ROS↓、LIP、Aβ1-42↓、ACSL4↓、p-BECN1↑、p-Tau↓、FPN↑、STEAP3、DMT1
大黄酚	SD大鼠（D-半乳糖造模）	0.036 mg/mL	GPx↑、GSH↑、GPX4↑、ROS↓、GAPDH、Aβ
麝香水提物	HT22细胞	330 μg/mL、60 μg/mL	MDA↓、GSH↑、ROS↓、GPX4↑、SLC7A11↑、TFRC↓、Fpn1↑、FTH1↑、Fe²⁺、Nrf2、Keap1↓、HO-1、FTH1
茯苓酸	SD大鼠（Aβ25-35诱导）	50 mg/kg	Nrf2、SLC7A11、GPX4↑、GSH↑、MDA↓、Fe²⁺↓

中药提取物调控铁死亡改善阿尔茨海默病的研究新进展

Research Progress in the Study of Traditional Chinese Herbal Medicine Extracts Regulating Ferroptosis thus Improving the Symptom of Alzheimer's Disease

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 81

相关文章 15

编辑推荐

Metrics

留言

[1]	李静, 刘子琦, 钱莉, 姚瑞芹. 微生物-肠-脑轴在癫痫中的作用研究进展[J]. 中国全科医学, 2026, 29(32): 4821-4826.
[2]	赵麒羽, 李欣悦, 吴民民, 陈秋欣. 线粒体在脑出血后铁死亡中的调控机制和靶向治疗研究新进展[J]. 中国全科医学, 2026, 29(32): 4827-4832.
[3]	谭丽博, 刘南阳, 李浩. 中成药治疗阿尔茨海默病临床研究的证据图分析[J]. 中国全科医学, 2026, 29(32): 4805-4814.
[4]	李姣, 向庆伟, 刘进进, 彭朗, 周剑杰, 杨琼, 梅应兵, 柳慧, 方英嵩, 谭子虎. 阿尔茨海默病患者跌倒相关住院风险预测模型的构建与验证研究[J]. 中国全科医学, 2026, 29(32): 4721-4729.
[5]	王诗怡, 范小静, 司亚飞, 周忠良. 健康老龄化背景下老年人内在能力关键测量技术的研究进展[J]. 中国全科医学, 2026, 29(31): 4662-4666.
[6]	贺洋, 杨荣, 沈灿, 易珊烨, 刘力滴, 赵茜, 万智, 廖晓阳. 衰弱轨迹及其影响因素研究进展[J]. 中国全科医学, 2026, 29(30): 4372-4378.
[7]	赵家义, 樊剑, 于德华. 1秒率正常的肺功能受损人群现状、挑战及应对策略[J]. 中国全科医学, 2026, 29(30): 4366-4371.
[8]	李喜玲, 张帆, 杨欣月, 杨姮. "零食式锻炼"在慢性病管理中应用的范围综述[J]. 中国全科医学, 2026, 29(30): 4472-4479.
[9]	李姣, 周剑杰, 彭朗, 梅应兵, 谭子虎. 阿尔茨海默病合并社区获得性肺炎发生不良预后风险预测模型的构建与验证研究[J]. 中国全科医学, 2026, 29(29): 4248-4257.
[10]	陈毓婧, 王岩, 李光, 董本超, 杨培川, 马剑雄. 数字技术在亚洲地区老年人肌少症干预中应用的范围综述[J]. 中国全科医学, 2026, 29(29): 4200-4210.
[11]	解霄芸, 刘晨曦, 柳羽姝, 周艺涵. 中国基层医疗卫生机构人工智能研究实践及潜在数据贫困问题：一项范围综述[J]. 中国全科医学, 2026, 29(28): 4067-4077.
[12]	姜妍琳, 王喆, 翟睿, 张梦洁, 陈溪, 王俊宏. 中药复方治疗注意缺陷多动障碍优势方案筛选研究：基于网状Meta分析和熵权TOPSIS法[J]. 中国全科医学, 2026, 29(27): 3985-3994.
[13]	冯雅晨, 刘乐伟, 薛金月, 孙先林, 刘寰忠. 可穿戴技术在精神障碍诊疗中的研究进展[J]. 中国全科医学, 2026, 29(27): 4016-4025.
[14]	杜若芳, 曹阳, 刘殿娜, 张祺昕, 王潇凡, 史恩泽, 张语馨, 李泉旺. 生半夏治疗肿瘤的10年临床回顾：用药模式及安全性评估[J]. 中国全科医学, 2026, 29(27): 3995-4003.
[15]	李海瑾, 朱宸立, 李卉, 冯郑文, 乔雨晨, 杜娟. 失智症诊断后管理相关指南的质量评价与内容分析[J]. 中国全科医学, 2026, 29(25): 3569-3576.